387 related articles for article (PubMed ID: 35274723)
21. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Heath EI; Rosenberg JE
Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
[TBL] [Abstract][Full Text] [Related]
22. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
[TBL] [Abstract][Full Text] [Related]
23. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
25. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Hashimoto H; Tanaka Y; Murata M; Ito T
Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
[TBL] [Abstract][Full Text] [Related]
26. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
Azizi A; Houshyar R; Mar N
J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
[TBL] [Abstract][Full Text] [Related]
27. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
[TBL] [Abstract][Full Text] [Related]
28. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
29. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.
Wu S; Adamson AS
Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865407
[TBL] [Abstract][Full Text] [Related]
31. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M; Nishimura N; Oda Y; Miyamoto T; Ohmori C; Takamatsu N; Itami Y; Tachibana A; Matsumoto Y; Kiba K; Tomioka A; Yamamoto H; Okajima E; Masaomi K; Sakamoto K; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
Jpn J Clin Oncol; 2024 Mar; 54(3):329-338. PubMed ID: 38061911
[TBL] [Abstract][Full Text] [Related]
32. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
33. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
[TBL] [Abstract][Full Text] [Related]
34. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
35. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
36. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
[No Abstract] [Full Text] [Related]
37. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
38. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
[TBL] [Abstract][Full Text] [Related]
39. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
Hoffman-Censits J; Lombardo K; McConkey D; Hahn NM; Bashir B; Kelly WK; Johnson B; Matoso A
Urol Oncol; 2021 Oct; 39(10):619-622. PubMed ID: 34148797
[TBL] [Abstract][Full Text] [Related]
40. [Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
Matte P; Campedel L
Bull Cancer; 2022; 109(7-8):738-740. PubMed ID: 35606195
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
